2025
Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Njei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchConceptsNon-lean individualsAll-cause mortalityMajor adverse cardiovascular eventsIncreased risk of all-cause mortalityRisk of all-cause mortalityVeterans Health AdministrationRisk of hepatic decompensationPrevalence of diabetesRisk of cardiovascular mortalityHepatic decompensationHigher mortality riskCardiovascular-related mortalityCox proportional hazards modelsCohort study of patientsCardiovascular outcomesIncident major adverse cardiovascular eventsRetrospective cohort study of patientsProportional hazards modelNon-HispanicRetrospective cohort studyCompeting risk regressionHealth AdministrationMultivariate Cox proportional hazards modelLean individualsAssessed associationsLiver Fibrosis and Cardiovascular Events
Nso N, Bookani K, Trimingham M, Orji R, Njei B, Balasubramanian S, Pursnani A. Liver Fibrosis and Cardiovascular Events. Southern Medical Journal 2025, 118: 19-25. PMID: 39753232, DOI: 10.14423/smj.0000000000001769.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesHumansLiver CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsSeverity of Illness IndexConceptsLiver fibrosis scoresNonalcoholic fatty liver diseaseRisk of cardiovascular eventsNAFLD fibrosis scoreCardiovascular eventsAll-cause mortalityFibrosis scoreLiver fibrosisSystematic reviewFibrosis-4Noninvasive liver fibrosis scoresLiver diseaseCardiovascular mortalityHigh risk of cardiovascular eventsNonalcoholic fatty liver disease fibrosis scoreRelevant prospective studiesSeverity of liver fibrosisNational Institutes of Health toolCardiovascular diseaseHigher liver fibrosis scoresSpectrum of cardiovascular diseasesFibrosis-4 scoreSeverity of fibrosisCardiovascular event occurrenceChronic liver disease
2024
The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades
Al Ta’ani O, Aleyadeh W, Al-Ajlouni Y, Alnimer L, Ismail A, Natour B, Njei B. The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades. BMC Public Health 2024, 24: 2979. PMID: 39468483, PMCID: PMC11514855, DOI: 10.1186/s12889-024-20445-5.Peer-Reviewed Original ResearchConceptsAge-standardized incidence rateAge-standardized death ratesDisability-adjusted life yearsBurden of cirrhosisGlobal Burden of DiseaseDisability burdenDeath rateAge-standardized disability-adjusted life yearsPublic health effortsBurden of diseaseSignificant health challengesGender-specific interventionsLiver disease incidenceChronic liver diseaseIncident casesMENA regionHealth effortsCountry-specific trendsHealthcare systemGlobal burdenHealth challengesIncreasing burdenIncidence rateLife yearsEpidemiological trends
2019
Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis
Kaplan DE, Serper M, Mehta R, Fox R, John B, Aytaman A, Baytarian M, Hunt K, Albrecht J, Njei B, Taddei TH, Group V. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019, 156: 1693-1706.e12. PMID: 30660733, DOI: 10.1053/j.gastro.2019.01.026.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularCholesterolFemaleHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLiver CirrhosisLiver NeoplasmsMaleMiddle AgedMyocardial InfarctionPropensity ScoreProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesStrokeSurvival RateUnited StatesConceptsRetrospective cohort studyStatin exposureLarge national cohortHepatic decompensationStatin useCohort studyHazard ratioNational cohortMultivariable Cox proportional hazards modelsCox proportional hazards modelBaseline total cholesterolPrior statin exposureStatin-naïve subjectsEffect of hypercholesterolemiaVeterans Health AdministrationProportional hazards modelHepatocellular carcinoma developmentDecrease of mortalityRisk-set matchingChild-TurcottePugh classStatin therapyDL increaseTotal cholesterolHepatic functionNational Trends in Use of Opioid Drugs Among Cirrhosis-related Hospitalizations in the United States, 2004 to 2012
McCarty TR, Haque L, Njei B. National Trends in Use of Opioid Drugs Among Cirrhosis-related Hospitalizations in the United States, 2004 to 2012. Journal Of Clinical Gastroenterology 2019, 53: 78-79. PMID: 27984400, DOI: 10.1097/mcg.0000000000000771.Peer-Reviewed Original Research
2016
Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta‐analysis
Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta‐analysis. Journal Of Gastroenterology And Hepatology 2016, 31: 1684-1693. PMID: 26952020, PMCID: PMC5014713, DOI: 10.1111/jgh.13337.Peer-Reviewed Original ResearchMeSH KeywordsCoinfectionElasticity Imaging TechniquesHepatitis CHIV InfectionsHumansLiver CirrhosisSensitivity and SpecificityConceptsHIV-HCV coinfectionTransient elastographyMeta-regression analysisDiagnostic accuracyLiver stiffnessModerate fibrosisPooled sensitivityHCV mono-infected individualsMono-infected individualsCD4 cell countCochrane Library databasesAssessment of cirrhosisSearch of PubMedNoninvasive imaging modalityNegative likelihood ratioWeb of ScienceLiver fibrosisInclusion criteriaLibrary databasesCirrhosisCell countSystematic reviewPublication biasPatientsFibrosisOptimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD scoreBeta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters
Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut 2016, 65: 1393. PMID: 27207973, DOI: 10.1136/gutjnl-2016-312129.Peer-Reviewed Original Research
2013
Increased mortality with peptic ulcer bleeding in patients with both compensated and decompensated cirrhosis
Venkatesh P, Parasa S, Njei B, Sanaka M, Navaneethan U. Increased mortality with peptic ulcer bleeding in patients with both compensated and decompensated cirrhosis. Gastrointestinal Endoscopy 2013, 79: 605-614.e3. PMID: 24119507, DOI: 10.1016/j.gie.2013.08.026.Peer-Reviewed Original ResearchConceptsInternational Classification of DiseasesPopulation-based studyHospital costsImpact of cirrhosisClassification of DiseasesPeptic ulcer bleedingIncreased mortalityAssociated with increased mortalityLength of stayInternational ClassificationIn-hospital mortalityControl groupStratified analysisAdministrative dataDecompensated cirrhosisHigher mortalityCompensated cirrhosisProportion of patientsAssociated with worse outcomesUlcer bleedingMortalityHospitalOutcomesOutcomes of patientsPresence of cirrhosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply